

FOR IMMEDIATE DISTRIBUTION



**CUMBERLAND PHARMACEUTICALS TO PRESENT AT
THE BMO CAPITAL MARKETS 10TH ANNUAL FOCUS ON HEALTHCARE
CONFERENCE IN NEW YORK**

NASHVILLE, Tenn. (July 26, 2010) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the BMO Capital Markets 10th Annual Focus on Healthcare Conference at the Sheraton New York Hotel & Towers in New York City on Thursday, August 5, 2010 at 3:30 p.m. Eastern Time.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast a replay will also be available on the Company website.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote[®] for the treatment of acetaminophen poisoning, Caldolor[®], the first injectable treatment for pain and fever approved in the United States, and Kristalose[®], a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.

About BMO Capital Markets

Established in 1817 and based in Canada, BMO Financial Group serves more than 10 million personal, commercial, corporate and institutional customers in North America and internationally. The company's operating groups – Personal and Commercial Banking, BMO Bank of Montreal in Canada and Harris in the United States; Private Client Group, our wealth management business; and BMO Capital Markets – share one vision: to be the bank that defines great customer experience.

SOURCE: Cumberland Pharmaceuticals Inc.

Contact:

Angela Novak
Investor Relations

(615) 255-0068

investors@cumberlandpharma.com